Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4180217 | 0.83 | SIGMAR1 (0.57) | SIGMAR1ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL13861254 | 0.83 | SIGMAR1 (0.56) | SIGMAR1ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL28329410 | 0.82 | SIGMAR1 (0.51) | SIGMAR1ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL19199734 | 0.81 | SIGMAR1 (0.55) | SIGMAR1ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL13799649 | 0.80 | SIGMAR1 (0.65) | SIGMAR1ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL18227122 | 0.79 | SIGMAR1 (0.48) | SIGMAR1ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL4434497 | 0.79 | SIGMAR1 (0.53) | SIGMAR1ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL1328433 | 0.79 | CTSD (0.54) | SIGMAR1ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL2429327 | 0.79 | SIGMAR1 (0.56) | SIGMAR1ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL10046336 | 0.79 | SIGMAR1 (0.53) | SIGMAR1ALDH1A1MEN1KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109686-A1 | PYRIDAZIN-3(2H)-ONE AND PYRIDIN-2(1H)-ONE PARP INHIBITOR COMPOUNDS | AZKARRA THERAPEUTICS, INC. (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4594314-A1 | PYRIDAZIN-3(2H)-ONE AND PYRIDIN-2(1H)-ONE PARP INHIBITOR COMPOUNDS | Azkarra Therapeutics, Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| CN-119968364-A | Pyridazin-3 (2H) -one and pyridin-2 (1H) -one PARP inhibitor compounds | 阿兹卡拉疗法公司 | 2025-05-09 | — | — | CN | disclosed |
| WO-2024073133-A1 | PYRIDAZIN-3(2H)-ONE AND PYRIDIN-2(1H)-ONE PARP INHIBITOR COMPOUNDS | AZKARRA THERAPEUTICS, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260109686-A1 | PYRIDAZIN-3(2H)-ONE AND PYRIDIN-2(1H)-ONE PARP INHIBITOR COMPOUNDS | PARP2, PARP1, PARP11 | SIGMAR1 804/4885TP53 1475/4885ALDH1A1 1213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.